Pulse Biosciences
A development-stage medical device company.
Launch date
Employees
Market cap
€1.0b
Enterprise valuation
€1.0b (Public information from Sep 2024)
Share price
$18.73 PLSE
Hayward California (HQ)
Financials
Estimates*
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | - | - | 1.4m | <1m | - | - |
| % growth | - | - | - | - | (51 %) | - | - |
| EBITDA | (36.7m) | (46.8m) | (49.3m) | (63.0m) | (58.1m) | (42.4m) | - |
| % EBITDA margin | (5236 %) | - | - | (4444 %) | (8294 %) | - | - |
| Profit | (37.5m) | (47.0m) | (49.9m) | (63.7m) | (58.5m) | (42.2m) | (47.0m) |
| % profit margin | (5364 %) | - | - | (4489 %) | (8358 %) | - | - |
| EV / revenue | 251.9x | - | - | 297.3x | 168.4x | - | - |
| EV / EBITDA | -4.8x | -5.6x | -12.1x | -6.7x | -2.0x | -15.1x | - |
| R&D budget | 17.3m | 25.0m | 26.4m | 28.6m | 20.8m | 27.8m | - |
| R&D % of revenue | 2465 % | - | - | 2020 % | 2977 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $8.0m | Early VC | |
| N/A | N/A | IPO | |
| N/A | $5.0m | Post IPO Equity | |
$300k | Grant | ||
| N/A | $30.0m | Post IPO Equity | |
| N/A | $45.0m | Post IPO Equity | |
| N/A | $30.0m | Post IPO Equity | |
| N/A | $50.0m | Post IPO Equity | |
* | $65.0m | Post IPO Equity | |
* | N/A | $65.0m | Post IPO Equity |
* | N/A | $60.0m | Post IPO Equity |
| Total Funding | €7.5m | ||
Related Content
Recent News about Pulse Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.